Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results